A startup developing proprietary technology that utilizes fish-derived gut bacteria to enhance aquaculture fish growth and strengthen immunity. Centered on aquaculture support through bacterial cocktails, it also tackles land-based aquaculture and branded fish production.
A biotech startup developing T-cell and NK-cell therapies derived from low-immunogenicity iPS cells. It aims to provide new treatments for solid tumors and autoimmune diseases, contributing to the treatment of previously difficult-to-treat intractable diseases.
We are a biotech company leveraging technologies from the National Cerebral and Cardiovascular Center, Nagasaki University, and Osaka University. We are developing "BROTHERS," a proprietary technology that pairs a PNA strand with an antisense oligonucleotide (ASO). This PNA acts as a "safeguard" to significantly reduce the toxicity issues common in conventional oligonucleotide therapeutics. We drive growth through a dual-engine business model: advancing our in-house pipeline for intractable diseases and out-licensing our platform via collaborations with pharmaceutical companies.
Business Utilizing Odor Quantification Technology Based on Olfactory Receptor Responses
Solving challenges in manufacturing, construction, and infrastructure with proprietary AI that leverages even limited data. A startup supporting operational efficiency and labor savings, aiming for a future where humans and AI coexist.